• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Reduced Doses of Direct Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation
【24h】

Reduced Doses of Direct Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation

机译：减少缺血性卒中患者的直接口服抗凝血剂的剂量减少，患有非衰弱性心房颤动

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The choice of standard or reduced doses of direct oral anticoagulants (DOACs) depends on patients' age, body weight, and renal function based on package instructions. Our aim was to conduct a simulation of DOAC dose using patients' data obtained on admission. Methods: This retrospective study included 314 ischemic stroke patients with nonvalvular atrial fibrillation admitted to our hospital between September 2014 and February 2018. Data on age, body weight, creatinine, and creatinine clearance were collected for each subject, and simulation was conducted for the dose of each DOAC. Results: The mean age of 314 subjects was 77.2 years; those aged 75 years or older accounted for 61.5% (193 patients). It was suggested that a standard dose of rivaroxaban could be used in 67.5% of patients and that of apixaban in 65.9%. By contrast, a standard dose of dabigatran could be used in only 16.9% of patients and that of edoxaban in only 32.5%. The simulation analysis for patients aged 75 years or older showed that a standard dose of rivaroxaban could be used in 54.9% of patients and that of apixaban in 44.6%, while that of edoxaban could be used in only 19.7% of patients. Conclusions: When DOACs are prescribed for secondary prevention of cerebral infarction in patients with nonvalvular atrial fibrillation, the rate of standard or reduced dose varies depending on the kind of DOAC. Further analysis is required to clarify whether a standard dose of one DOAC or reduced dose of another DOAC yields the best result for each patient.
机译：背景：标准或减少剂量的直接口服抗凝血剂（DOAC）的选择取决于患者年龄，体重和基于包装指示的肾功能。我们的目的是使用在入院时使用患者的数据进行DOAC剂量的模拟。方法：该回顾性研究包括2014年9月和2018年2月在我们院内接受了314例缺血性脑卒中患者，从2018年9月期间录取了我们的医院。对每个受试者进行年龄，体重，肌酐和肌酐清除的数据，并对剂量进行模拟每个Doac。结果：314名科目的平均年龄为77.2岁; 75岁或以上的人占61.5％（193名患者）。有人建议，标准剂量的蓖麻毒素可用于67.5％的患者和65.9％的紫杉醇。相比之下，Dabigatran的标准剂量可用于仅为16.9％的患者和Edoxaban只有32.5％。 75岁或以上患者的仿真分析显示，标准剂量的rivaroxaban可用于54.9％的患者和紫杉醇中的44.6％，而Edoxaban的患者可仅用于19.7％的患者。结论：当NoAcular患者中脑梗死的二次预防脑梗死时，标准或减少剂量率取决于DOAC的种类。需要进一步分析来澄清一个DoAC的标准剂量是否为另一个DOAC的DOAC或减少剂量产生了每位患者的最佳结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号